rosiglitazone has been researched along with Hip Fractures in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| de Boer, A; Groenwold, RH; Hoes, AW; Klugkist, I; Klungel, OH; Nielen, M; Schmidt, AF | 1 |
| Colhoun, HM; Donnan, PT; Guthrie, B; Leese, GP; Lindsay, RS; Livingstone, SJ; Looker, HC; McKeigue, P; McKnight, J; Morris, AD; Pearson, DW; Pearson, E; Petrie, JR; Philip, S; Reed, C; Sattar, N; Sullivan, FM; Wild, SH | 1 |
2 other study(ies) available for rosiglitazone and Hip Fractures
| Article | Year |
|---|---|
Bayesian methods including nonrandomized study data increased the efficiency of postlaunch RCTs.
Topics: Bayes Theorem; Bias; Computer Simulation; Female; Hip Fractures; Humans; Male; Randomized Controlled Trials as Topic; Research Design; Rosiglitazone; Sample Size; Thiazolidinediones | 2015 |
Hospitalised hip fracture risk with rosiglitazone and pioglitazone use compared with other glucose-lowering drugs.
Topics: Age Distribution; Aged; Databases, Factual; Diabetes Mellitus, Type 2; Drug Prescriptions; Female; Follow-Up Studies; Hip Fractures; Hospitalization; Humans; Hypoglycemic Agents; Male; Middle Aged; Pharmacoepidemiology; Pioglitazone; Risk Factors; Rosiglitazone; Scotland; Sex Distribution; Thiazolidinediones | 2012 |